Skip to main content
Atrás
IVBXF logo

Innovent Biologics, Inc.

Calidad de datos: 100%
IVBXF
OTC Healthcare Biotechnology
$9.75
▼ $1.02 (-9.47%)
Cap. Mercado: 16.78B
Rango del Día
$9.75 $11.36
Rango de 52 Semanas
$5.00 $15.12
Volumen
200
Promedio 50D / 200D
$10.76 / $11.34
Cierre Anterior
$10.77

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E -177.3 0.4
P/B 1.3 2.9
ROE % -0.7 3.7
Net Margin % -1.0 3.9
Rev Growth 5Y % 25.1 10.0
D/E 0.2 0.2

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2029 $5.70
$3.93 – $9.22
41 B 1
FY2028 $5.68
$3.92 – $9.19
32 B 1
FY2027 $2.53
$1.74 – $4.09
22 B 1

Puntos Clave

Revenue grew 25.12% annually over 5 years — strong growth
Debt/Equity of 0.22 — conservative balance sheet
Negative free cash flow of -418.39M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 26.70%

Crecimiento

Revenue Growth (5Y)
25.12%
Revenue (1Y)51.82%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-0.74%
ROIC-3.55%
Net Margin-1.00%
Op. Margin-8.02%

Seguridad

Debt / Equity
0.22
Current Ratio2.35
Interest Coverage-11.17

Valoración

P/E Ratio
-177.30
P/B Ratio1.28
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 51.82% Revenue Growth (3Y) 43.80%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 25.12% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 9.42B Net Income (TTM) -94.63M
ROE -0.74% ROA -0.44%
Gross Margin 83.97% Operating Margin -8.02%
Net Margin -1.00% Free Cash Flow (TTM) -418.39M
ROIC -3.55% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.22 Current Ratio 2.35
Interest Coverage -11.17 Dividend Yield 0.00%
Valuation
P/E Ratio -177.30 P/B Ratio 1.28
P/S Ratio 1.78 PEG Ratio 6.00
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 16.78B Enterprise Value 12.10B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 9.42B 6.21B 4.56B 4.27B 3.84B
Net Income -94.63M -1.03B -2.18B -2.73B -998.42M
EPS (Diluted) -0.06 -0.66 -1.46 -1.88 -0.74
Gross Profit 7.91B 4.40B 3.63B 3.70B 3.46B
Operating Income -755.87M -1.68B -3.12B -2.70B -557.19M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 21.60B 20.63B 17.59B 16.24B 11.83B
Total Liabilities 8.48B 8.10B 6.86B 5.91B 3.06B
Shareholders' Equity 13.12B 12.53B 10.73B 10.33B 8.78B
Total Debt 2.83B 3.62B 3.23B 2.50B 1.21B
Cash & Equivalents 7.51B 10.05B 1.02B 1.36B 1.28B
Current Assets 10.27B 13.43B 11.51B 11.55B 9.47B
Current Liabilities 4.37B 4.48B 3.50B 3.05B 1.49B